Information Provided By: 
Fly News Breaks for September 25, 2017
AMDA
Sep 25, 2017 | 13:50 EDT
As previously reported, Maxim analyst Jason Kolbert downgraded Amedica to Hold from Buy saying that while he fundamentally believes its silicon nitride product line represents a paradigm shift in the implant industry, the company has been hampered by a lack of capital. With just about $2.5M in cash remaining on the balance sheet, the company will need to raise capital, he adds.
News For AMDA From the Last 2 Days
There are no results for your query AMDA
